Ventripoint Diagnostics Ltd.
TSX VENTURE : VPT

Ventripoint Diagnostics Ltd.

March 02, 2017 07:00 ET

Approval for World's First Complete Heart Analysis System for 2D Ultrasound Exams Received by Ventripoint

TORONTO, ONTARIO--(Marketwired - March 2, 2017) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSX VENTURE:VPT) announces that it has received a license from Health Canada for the new VMS-PLUS™ machine and the 4-chamber (4C) heart analysis system. This is an expansion of the VMS heart analysis product to include right atrium (RA), left atrium (LA) and left ventricle (LV) chambers of the heart. The VMS was already licensed in Canada for use for the right ventricle (RV). This expansion allows for the determination of volume and function for all four chambers of the heart using conventional 2D ultrasound, which could only be provided by MRI until now.

"Ventripoint has achieved a "world first" with the approval of a whole-heart analysis system for 2D ultrasound exams, which provides accurate and reliable measurements equivalent to MRI," stated Dr. George Adams, CEO of Ventripoint. "I am excited to begin to market our 4C machine and generate value for our shareholders. With the license in Canada, Ventripoint now has "home-country approval", which simplifies the registration process for VMS products in many countries. This is exactly what we've been striving for."

The size and function of all four chambers of the heart is increasingly recognized as critically important in monitoring patients' responses to cardiac medications and procedures and predicting outcomes This information is often unavailable as access to cardiac MRI is very limited in many countries, including Canada. 2D cardiac ultrasound is universally available worldwide and with the VMS-PLUS generates measurements equivalent to MRI. This simple combination makes it possible to obtain this valuable information at every cardiology appointment in a few minutes.

Forward Looking Statements:

The information in this release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information